Xencor (XNCR) Short-term Investments (2015 - 2026)
Xencor (XNCR) posted quarterly Short-term Investments of $370.2 million for Q1 2026, up 657.53% year-over-year from $48.9 million in Q1 2025, and down 2.87% quarter-over-quarter from $381.2 million in Q4 2025.
Analysis
Xencor (XNCR) Short-term Investments (2015 - 2026) Analysis & Trends
Xencor (XNCR) has reported Short-term Investments for 12 consecutive years, with $370.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Short-term Investments rose 657.53% year-over-year to $370.2 million; the TTM figure through Mar 2026 stood at $370.2 million (up 657.53% YoY), while the FY2025 annual figure was $381.2 million, down 6.8% from the prior year.
- Short-term Investments eased to $370.2 million in Q1 2026 per XNCR's latest filing, from $381.2 million in the prior quarter.
- Across five years, Short-term Investments topped out at $497.7 million in Q4 2023 and bottomed at $26.9 million in Q2 2022.
- Historically, Short-term Investments has averaged $193.3 million across 5 years, with a median of $48.9 million in 2025.
- Annual changes were most pronounced in 2022 — Short-term Investments plunged 90.94% — and 2023, when it surged 1182.71%.
- Xencor's Short-term Investments stood at $42.4 million in 2022, then surged by 1073.02% to $497.7 million in 2023, then retreated by 17.83% to $409.0 million in 2024, then decreased by 6.8% to $381.2 million in 2025, then dropped by 2.87% to $370.2 million in 2026.
- Business Quant data shows XNCR's Short-term Investments at $370.2 million in Q1 2026, $381.2 million in Q4 2025, and $84.3 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 333.15 Mn |
| Mar 31, 2026 | 370.21 Mn |
| Dec 31, 2025 | 381.16 Mn |
| Sep 30, 2025 | 358.49 Mn |
| Jun 30, 2025 | 358.98 Mn |
| Mar 31, 2025 | 381.02 Mn |
| Dec 31, 2024 | 408.97 Mn |
| Sep 30, 2024 | 435.04 Mn |
| Jun 30, 2024 | 449.37 Mn |
| Mar 31, 2024 | 460.37 Mn |
| Dec 31, 2023 | 497.73 Mn |
| Sep 30, 2023 | 412.83 Mn |
| Jun 30, 2023 | 476.67 Mn |
| Mar 31, 2023 | 475.92 Mn |
| Dec 31, 2022 | 526.69 Mn |
| Sep 30, 2022 | 515.40 Mn |
| Jun 30, 2022 | 435.62 Mn |
| Mar 31, 2022 | 278.06 Mn |
| Dec 31, 2021 | 153.77 Mn |
| Sep 30, 2021 | 199.42 Mn |